{
  "guid": "76da028f-6c3a-4bbd-8221-fcf65cb82aee",
  "title": "The Struggles of India’s Vaccine Giant",
  "description": "<p>When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations. </p><p>Earlier this year, a ban instituted by Prime Minister Narendra Modi put a stop to those plans. </p><p>What has that meant for the nations promised millions of doses?</p><p>Guest: <a href=\"https://www.nytimes.com/by/emily-schmall?smid=pc-thedaily\">Emily Schmall</a>, a South Asia correspondent for The New York Times based in New Delhi. </p><p><a href=\"https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily\">Sign up here</a> to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, <a href=\"https://www.nytimes.com/newsletters/the-daily?module=inline\">subscribe to our newsletter</a>. </p><p>Background reading: </p><ul><li>The Serum Institute vowed to protect its country from the coronavirus and inoculate the world’s poor, but <a href=\"https://www.nytimes.com/2021/05/07/world/india-serum-institute-covid19.htmlThe%20Serum%20Institute%20vowed%20to%20protect%20the%20country%20from%20the%20coronavirus%20and%20inoculate%20the%20world%E2%80%99s%20poor,%20but%20India%E2%80%99s%20crisis%20has%20pushed%20it%20past%20its%20limits.%20%20Big-power%20muscle%20flexing%20helps%20explain%20much%20of%20the%20world%E2%80%99s%20vaccine%20inequities,%20but%20there%E2%80%99s%20another%20reason%20behind%20insufficient%20doses:%20The%20challenge%20of%20making%20them%20is%20unprecedented.\">India’s crisis has pushed it past its limits</a>.</li><li>Big-power muscle flexing helps explain many of the world’s vaccine inequities, but there’s another problem: <a href=\"https://www.nytimes.com/2021/05/03/world/global-coronavirus-vaccine-shortage.htmlThe%20Serum%20Institute%20vowed%20to%20protect%20the%20country%20from%20the%20coronavirus%20and%20inoculate%20the%20world%E2%80%99s%20poor,%20but%20India%E2%80%99s%20crisis%20has%20pushed%20it%20past%20its%20limits.%20%20Big-power%20muscle%20flexing%20helps%20explain%20much%20of%20the%20world%E2%80%99s%20vaccine%20inequities,%20but%20there%E2%80%99s%20another%20reason%20behind%20insufficient%20doses:%20The%20challenge%20of%20making%20them%20is%20unprecedented.\">The manufacturing challenge is unprecedented</a>.</li></ul><p>For more information on today’s episode, visit <a href=\"http://nytimes.com/thedaily?smid=pc-thedaily\">nytimes.com/thedaily</a>. Transcripts of each episode will be made available by the next workday. </p>\n",
  "pubDate": "Thu, 24 Jun 2021 09:45:00 +0000",
  "author": "thedaily@nytimes.com (The New York Times)",
  "link": "https://www.nytimes.com/the-daily",
  "content:encoded": "<p>When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations. </p><p>Earlier this year, a ban instituted by Prime Minister Narendra Modi put a stop to those plans. </p><p>What has that meant for the nations promised millions of doses?</p><p>Guest: <a href=\"https://www.nytimes.com/by/emily-schmall?smid=pc-thedaily\">Emily Schmall</a>, a South Asia correspondent for The New York Times based in New Delhi. </p><p><a href=\"https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily\">Sign up here</a> to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, <a href=\"https://www.nytimes.com/newsletters/the-daily?module=inline\">subscribe to our newsletter</a>. </p><p>Background reading: </p><ul><li>The Serum Institute vowed to protect its country from the coronavirus and inoculate the world’s poor, but <a href=\"https://www.nytimes.com/2021/05/07/world/india-serum-institute-covid19.htmlThe%20Serum%20Institute%20vowed%20to%20protect%20the%20country%20from%20the%20coronavirus%20and%20inoculate%20the%20world%E2%80%99s%20poor,%20but%20India%E2%80%99s%20crisis%20has%20pushed%20it%20past%20its%20limits.%20%20Big-power%20muscle%20flexing%20helps%20explain%20much%20of%20the%20world%E2%80%99s%20vaccine%20inequities,%20but%20there%E2%80%99s%20another%20reason%20behind%20insufficient%20doses:%20The%20challenge%20of%20making%20them%20is%20unprecedented.\">India’s crisis has pushed it past its limits</a>.</li><li>Big-power muscle flexing helps explain many of the world’s vaccine inequities, but there’s another problem: <a href=\"https://www.nytimes.com/2021/05/03/world/global-coronavirus-vaccine-shortage.htmlThe%20Serum%20Institute%20vowed%20to%20protect%20the%20country%20from%20the%20coronavirus%20and%20inoculate%20the%20world%E2%80%99s%20poor,%20but%20India%E2%80%99s%20crisis%20has%20pushed%20it%20past%20its%20limits.%20%20Big-power%20muscle%20flexing%20helps%20explain%20much%20of%20the%20world%E2%80%99s%20vaccine%20inequities,%20but%20there%E2%80%99s%20another%20reason%20behind%20insufficient%20doses:%20The%20challenge%20of%20making%20them%20is%20unprecedented.\">The manufacturing challenge is unprecedented</a>.</li></ul><p>For more information on today’s episode, visit <a href=\"http://nytimes.com/thedaily?smid=pc-thedaily\">nytimes.com/thedaily</a>. Transcripts of each episode will be made available by the next workday. </p>\n",
  "enclosure": "",
  "itunes:title": "The Struggles of India’s Vaccine Giant",
  "itunes:author": "The New York Times",
  "itunes:duration": "00:28:02",
  "itunes:summary": "When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations. \nEarlier this year, a ban instituted by Prime Minister Narendra Modi put a stop to those plans. \nWhat has that meant for the nations promised millions of doses?\n\nGuest: Emily Schmall, a South Asia correspondent for The New York Times based in New Delhi.",
  "itunes:subtitle": "When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations. \nEarlier this year, a ban instituted by Prime Minister Narendra Modi put a stop to those plans. \nWhat has that meant for the nations promised millions of doses?\n\nGuest: Emily Schmall, a South Asia correspondent for The New York Times based in New Delhi.",
  "itunes:explicit": "no",
  "itunes:episodeType": "full"
}